ArticleJournal of cancer research and clinical oncology2025
Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss intervention.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate various body fat indicators under weight management on the time to complete response (CR) in overweight patients undergoing fertility-sparing treatment for endometrial cancer (EC) or atypical hyperplasia (AEH).
methodsClinical data and weight indicators of obese patients (percent body fat ≥ 30%) with AEH or early-stage EC who received fertility-sparing treatment from 2018 to 2023 were retrospectively collected from the Peking Union Medical College Hospital. Cox proportional hazards regression analysis was used for univariate and multivariate analyses.
resultsFifty-three patients with AEH (45.28%) or EC (54.72%) were finally included. Percent body fat > 8% (p = 0.018) was identified as an independent predictor of time to CR. Patients with body fat mass loss > 15%, and percent body fat loss > 8% had a lower recurrence rate (p = 0.043 and p = 0.007, respectively). Patients with visceral fat area loss > 18%, body fat mass loss > 15%, and percent body fat loss > 8% had a slightly higher pregnancy rate.
conclusionWhen overweight patients with AEH or EC receive fertility-sparing treatment, multiple body fat indicators, especially the loss of percent body fat, are more meaningful for evaluating the time to CR, recurrence rate, and pregnancy rate than weight loss. Registration: ChiCTR2200067099
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.